The Priority Review

Clinical trials Brief

Alexion posts results of Phase 3 ARTEMIS ravulizumab trial

The company posted results for its Phase 3 ARTEMIS study, which enrolled 555 participants and was terminated after primary completion on October 7, 2025. The trial assessed a single dose of ravulizumab IV versus placebo in adult participants with CKD undergoing non-emergent cardiac surgery with cardiopulmonary bypass.

Primary source

ClinicalTrials.gov results record, October 29, 2026

ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE

Read the source clinicaltrials.gov

By The Priority Review desk. Machine-summarized from the source above; not independently reported. How we use automation